GEORGE R BLUMENSCHEIN to Clinical Trials, Phase II as Topic
This is a "connection" page, showing publications GEORGE R BLUMENSCHEIN has written about Clinical Trials, Phase II as Topic.
Connection Strength
0.122
-
Plasma biomarkers correlating with clinical outcome in a phase II study of sorafenib in advanced NSCLC. Cancer Biomark. 2011-2012; 10(6):287-98.
Score: 0.074
-
Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies. J Clin Oncol. 2017 Sep 01; 35(25):2885-2892.
Score: 0.029
-
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst. 2012 Feb 08; 104(3):228-39.
Score: 0.020